Acrivon Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -8.54%
- Market cap
- $61.92M
- 42.85M shares
- Filings
- 351
—
—
—Q2 2026N/M FY25 yoy
Q2 2026N/M FY25 yoy
Q2 2026derivedN/M FY25 yoy
Q2 2026N/M FY25 yoy
Q2 2026+4.2% FY25 yoy
- $61.92M
- —
- —
- 0.7×
- -105.51%
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Research And Development
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $59,990,000 | reported | |
| FY 2024 | 2024-12-31 | $63,992,000 | reported | |
| FY 2023 | 2023-12-31 | $46,024,000 | reported | |
| FY 2022 | 2022-12-31 | $23,949,000 | reported |
Segments
Geography
LineFY2025ShareChange
United States$5.10M104%+4.1%
Lund, Sweden$2.30M47%−25.8%
Total$4.89M
Pharmaceutical preparations
Acrivon Therapeutics, Inc. is the 320th largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
LFVNLifevantage Corp$182.6M20.1%2.8%$64.0MRNTXRein Therapeutics, Inc.$0.0——$63.1MHRTXHeron Therapeutics, Inc.$154.9M7.4%13.0%$63.1MMAIAMAIA Biotechnology, Inc.———$63.0MTNXPTonix Pharmaceuticals Holding Corp.$13.1M29.8%946.2%$62.6M
ACRVAcrivon Therapeutics, Inc. (this company)———$61.9M
XBITXBiotech Inc.———$60.1MCLNNClene Inc.$200.0K41.5%13,086.5%$59.8MNMADNomad Power Solutions, Inc.———$59.7MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Acrivon Therapeutics, Inc. · CIK 1781174 · Engraved from SEC EDGAR